摘要
目的评估重酒石酸卡巴拉汀治疗阿尔茨海默病(AD)的有效性、安全性及耐受性。方法MMSE评分≤26分的32例AD患者,给予重酒石酸卡巴拉汀口服治疗16周。应用MMSE、ADAS-cog、Blessed-Roth量表评估药物治疗患者的认知功能和日常生活能力的疗效,并观察不良反应。结果经治疗,32例患者MMSE评分28例有明显改善(P<0.01),4例无变化;32例Blessed-Roth评分和29例ADAS-cog评分均显示治疗前后有明显改善(P<0.01)。不良反应主要为胃肠道不适。多数患者的有效剂量为9mg/d,分2次服用。结论重酒石酸卡巴拉汀是一种耐受性好,治疗AD安全有效的药物。
Objective:To evaluate the efficacy, safety and tolerance of Rivastigmine(Exelon), a centrally acting cholinesterase inhibitor, in the treatment of patients with Alzheimer’s disease(AD).Methods:Thirty two patients with AD who scored≤26 of mini mental status examination(MMSE)were enrolled into the present study. The cognitive function and ability to adapt to daily life of the patients were estimated with MMSE, ADAS-cog and Blessed-Roth scales. The untoward effects were also recorded. Results:In most patients, the effective dose of Rivastigmine was 9 mg per day . With the treatment of Rivastigmine, 28 cases observed remarkable improvement (P<0.01), and 4 cases did not observe significant improvement for MMSE; 32 cases and 29 cases observed significant improvement for Blessed-Roth and ADAS-cog respectively. The chief untoward effects were abdominal discomforts. Conclusion:Rivastigmine is an effective, safe and tolerable drug for the treatment of patients with AD.
出处
《上海医药》
CAS
2002年第8期358-360,共3页
Shanghai Medical & Pharmaceutical Journal
